These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141 [TBL] [Abstract][Full Text] [Related]
7. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial. Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report. Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406 [TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566 [TBL] [Abstract][Full Text] [Related]
10. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246 [TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient. Mitwalli AH; Nazmi A; Al Ghonaim M; Shaheen F; Kfoury H Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):80-5. PubMed ID: 23354197 [TBL] [Abstract][Full Text] [Related]
12. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir. Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294 [TBL] [Abstract][Full Text] [Related]
13. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140 [TBL] [Abstract][Full Text] [Related]
15. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914 [TBL] [Abstract][Full Text] [Related]
16. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769 [TBL] [Abstract][Full Text] [Related]
17. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of quantitative-PCR versus serology for detection of CMV in pre- and post- transplantation patients. Al-Attas SG; Shehata MI; Esmaeal HM; Radhwan NA Egypt J Immunol; 2010; 17(1):41-8. PubMed ID: 22053608 [TBL] [Abstract][Full Text] [Related]
19. Postural epigastric pain as a sign of cytomegalovirus gastritis in renal transplant recipients: a case-based review. Li W; Fan H; Yiping L Transplant Proc; 2009 Nov; 41(9):3956-8. PubMed ID: 19917423 [TBL] [Abstract][Full Text] [Related]
20. Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors. Schachtner T; Stein M; Reinke P Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28296035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]